Product Description

Semeglutide is a novel GLP-1 analogue administered subcutaneously once weekly. Semaglutide is a long-acting GLP-1 analogue developed by Novo Nordisk and administered subcutaneously once a week. Compared to liraglutide, semaglutide has a longer fat chain and increased hydrophobicity, but semaglutide is modified with a PEG short chain, and its hydrophilicity is greatly enhanced. After PEG modification, it can not only bind tightly to albumin, mask the hydrolysis site of DPP-4 enzyme, but also reduce renal excretion, prolong the biological half-life, and achieve the effect of long circulation. Novo Nordisk's semaglutide beats DPP-4's sitagliptin, the originator of GLP-1's long-acting exenatide (it should have been designed head-to-head with Eli Lilly's authenticity, bullying has long since declined in the market). In the trial, high doses of somatic cells reduced A1C by 1.6% and body weight by 6 kg. Semaglutide is a trial investigating the efficacy and safety of 1.0 mg semaglutide compared to exenatide administered once a week in 813 patients with type 2 diabetes for 56 weeks with 1-2 antidiabetic drugs taken orally.